MedTrace Logo

Alternative Treatment Strategies for Stenotrophomonas Maltophilia Pneumonia

NCT06112938 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2025-07-28

No results posted yet for this study

Summary

Multi center, retrospective chart review of patients admitted to MHS hospitals from April 1, 2017 to March 31, 2022. Patients will be identified through the electronic medical record, and data from those that meet the study inclusion and exclusion criteria will be analyzed. Minimum inhibitory concentration (MIC) data will be interpreted per Clinical \& Laboratory Standards Institute (CLSI) standards to determine local patterns of resistance. Multivariable logistic regression will be performed to determine predictors of mortality for S. maltophilia isolates.

Conditions

  • Stenotrophomonas Maltophilia Infection

Interventions

DRUG

Antibiotic

We aim to examine differences in clinical outcomes and failure rates between standard and alternative treatment strategies such as minocycline (or moxifloxacin, ciprofloxacin, ceftazidime) alone or in combination with TMP-SMX, alternative TMP-SMX dosing regimens, or variations in durations of therapy for the treatment of S. maltophilia infections within Methodist Health System (MHS).

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Mathew Crotty, PharmD · The Methodist Hospital Research Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-21
Primary Completion
2025-07-14
Completion
2025-07-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06112938 on ClinicalTrials.gov